Über uns
Affinivax was acquired by GSK in August 2022. Affinivax is a clinical stage biotechnology company developing a next generation approach in vaccine technologies to design both preventive and therapeutic vaccines that provide broader protection against infectious and other immune mediated diseases.
- Website
-
http://affinivax.com
External link for Affinivax Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Cambridge, Massachusetts
- Typ
- In Privatbesitz
Standorte
-
Primäre
Wegbeschreibung erhalten
Cambridge, Massachusetts, US